Drugs / ZW49
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03821233 | Apr 2019 → Sep 2024 | carcinoma | Zymeworks BC Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-18 | Zymeworks BC Inc. | Results Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting zymeworks.com ↗
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer |
| 2022-09-04 | Zymeworks BC Inc. | Results Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers zymeworks.com ↗
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZW49 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03821233 ↗ |
| Route | Intravenous | “ZW49 administered intravenously at dose levels determined by the SMC” NCT03821233 ↗ |